ClinicalTrials.gg
Not yet recruitingNCT07731945Updated Aug 10, 2026

Postoperative CCT in FECD vs. Non-FECD

An observational study in Fuchs Endothelial Corneal Dystrophy and Cataract (Post-operative Cataract Surgery Follow-up), sponsored by Vienna Hospital Association. Not yet recruiting. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Vienna Hospital Association · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
98
Ages
50 Years and older
Sex
All
01

Study summary

This single-centre, prospective, controlled, non-interventional observational clinical study aims to characterize early postoperative corneal thickness behaviour after routine phacoemulsification cataract surgery in eyes with Fuchs endothelial corneal dystrophy (FECD) compared with non-FECD controls, using exclusively standard-of-care perioperative assessments. To compare central corneal thickness (CCT) six weeks postoperatively between FECD and non-FECD eyes, adjusting for baseline (preoperative) CCT.

All participants undergo routine phacoemulsification cataract surgery and routine perioperative assessments. Data are collected from the standard-of-care documentation at the following time points:

  1. Preoperative baseline visit (routine cataract work-up)
  2. Study specific postoperative follow-up at approximately 6 weeks. Each participant will attend a study-specific follow-up visit at 6 weeks postoperatively and contributes study-specific follow-up data up to this time point.

The routine clinical parameters assessed (as available per standard practice) include:

(A) Medical history / baseline characteristics and documentation of ocular/systemic comorbidities and topical medication.

(B) Best-corrected visual acuity (BCVA) (logMAR).

(C) Intraocular pressure (IOP) measured by Goldmann applanation tonometry (GAT).

(D) Slit-lamp examination (including assessment of corneal clarity/edema and anterior segment findings) with fundoscopy as routinely documented.

(E) Central corneal thickness (CCT) measurement using routine clinical devices. All measurements will be performed at a consistent time of day for each patient.

(F) Anterior segment optical coherence tomography (AS-OCT) using Casia2.

(G) Anterior segment Scheimpflug tomography (Pentacam Oculus AXL).

(H) Endothelial cell assessment or Endothelial Cell Count (ECC) examined with NIDEK® CEM-530 Specular Microscope:

  • Cell Density (CD) or Cell Count. Expressed as Cells/mm²
  • Coefficient of Variation (CV), represents the degree of variation in cell size (Polymegethism)
  • Percentage (%) of six-sided (hexagon) cells (HEX)
  • Standard Deviation (SD) of the average cell area.
Read the detailed description

This is a single-centre, prospective, controlled, non-interventional observational clinical study conducted at the Augenabteilung, Klinik Hietzing, Wiener Gesundheitsverbund, Vienna, Austria.

Fuchs endothelial corneal dystrophy (FECD) is a progressive disorder of the corneal endothelium characterized clinically by central guttae and a gradual loss of endothelial barrier and pump function, ultimately leading to corneal edema, increased corneal thickness, and visual impairment. In FECD, thickening is primarily a consequence of stromal hydration (deturgescence failure), and corneal edema can be present even when it is not yet obvious on slit-lamp examination ("subclinical edema"), which complicates clinical staging and risk estimation in routine practice.

Because cataract prevalence increases with age, cataract and FECD frequently coexist, and cataract surgery planning in FECD must account for the reduced endothelial reserve. Phacoemulsification - although highly standardized and effective - exerts mechanical, ultrasonic, and fluidic stress on the endothelium and can cause postoperative endothelial cell loss even in otherwise healthy eyes. Large, randomized data have shown that modern cataract surgery can measurably affect the corneal endothelium and that the magnitude of endothelial impact depends on patient- and surgery-related factors. Clinically, inadequate endothelial pump function is a key mechanism underlying postoperative corneal edema after cataract surgery, making endothelial vulnerability a central safety consideration in FECD eyes.

Central corneal thickness (CCT) is a routinely available, quantitative parameter that reflects corneal hydration status and is commonly used in clinical decision making in FECD, because the central cornea thickens as edema develops. In FECD specifically, clinicians frequently incorporate CCT into perioperative assessment; however, isolated CCT values have limitations because normal corneas can occasionally be thick and because "pre-edematous" baseline thickness varies across individuals. As a result, thresholds (e.g., around 640 µm) have been proposed as practical indicators of clinically relevant edema in FECD, but the overlap between normal variation and early/subclinical disease underscores the need to interpret CCT in context and - when possible - relative to baseline.

In the postoperative setting, transient corneal swelling (reflected by increased CCT) is a well-recognized phenomenon after phacoemulsification, and it is mechanistically linked to surgical endothelial stress. Studies evaluating postoperative corneal swelling after phacoemulsification show that CCT can increase early after surgery and then trend back toward baseline in uncomplicated cases, whereas persistent edema is more likely when endothelial reserve is compromised. Moreover, postoperative corneal swelling has been shown to correlate with endothelial cell loss after phacoemulsification, supporting the use of CCT as a clinically meaningful, non-invasive outcome reflecting endothelial "load" in the early postoperative period.

From a methodological perspective, comparing postoperative CCT between FECD and non-FECD eyes requires careful handling of baseline variability, because corneal thickness differs substantially between individuals and baseline imbalance can bias or obscure group differences if not appropriately addressed. In controlled clinical studies with baseline and follow-up measurements, inclusion of the baseline value as a covariate in an analysis of covariance (ANCOVA) framework is widely recommended because it conditions the comparison on baseline, improves precision, and avoids the bias that can arise with alternative approaches (e.g., analysing change scores without proper adjustment), particularly when baseline and follow-up are correlated. This is directly aligned with the statistical objective of estimating the group effect on postoperative CCT while accounting for preoperative thickness heterogeneity.

Against this background, the present study is designed as a prospective, controlled, non-interventional observational clinical investigation to quantify early postoperative CCT outcomes after routine phacoemulsification in FECD compared with non-FECD controls. The primary objective is to compare CCT at 6 weeks postoperatively between groups while adjusting for baseline preoperative CCT using ANCOVA, thereby providing an interpretable, baseline-conditioned estimate of the association between FECD status and postoperative corneal thickness under real-world clinical conditions. Secondary objectives include characterizing the magnitude of postoperative CCT change relative to baseline and exploring whether baseline corneal/lens characteristics (including FECD severity graded by commonly used clinical grading frameworks) are associated with postoperative CCT trajectories. By relying exclusively on standard-of-care perioperative assessments, the study aims to generate clinically applicable evidence to support perioperative risk stratification and patient counselling in FECD patients undergoing cataract surgery.

02

Conditions studied

  • Fuchs Endothelial Corneal Dystrophy
  • Cataract (Post-operative Cataract Surgery Follow-up)

Keywords

  • Postoperative CCT
  • Fuchs Endothelial Corneal Dystrophy
  • FECD
  • CCT in FECD
  • Cataract Surgery FECD
03

In context

Fuchs' Endothelial Dystrophy

92 studies on the registry are indexed under Fuchs' Endothelial Dystrophy; 27 are open to participants now.

This study's planned enrollment of 98 is below the median of 144 across 26 observational studies indexed under Fuchs' Endothelial Dystrophy.

Browse Fuchs' Endothelial Dystrophy studies →

Lead sponsor

Vienna Hospital Association is the lead sponsor of 11 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study will include approximately 98 eyes scheduled for routine phacoemulsification cataract surgery at the Augenabteilung, Klinik Hietzing, Wiener Gesundheitsverbund (Vienna, Austria). The indication to perform cataract surgery will have been made prior to and independently of study participation. Participants will be enrolled from the routine cataract surgery population and allocated to one of two cohorts based on the presence or absence of Fuchs endothelial corneal dystrophy (FECD) as determined during standard preoperative assessment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written for participation and for use of routine clinical data in pseudonymised form.
  2. Age ≥50 years at the time of cataract surgery.
  3. Scheduled cataract surgery (unilateral/bilateral cataract).
  4. No evidence of other ophthalmic diseases (e.g. macular pathology)

    Cohort-specific inclusion:

  5. FECD cohort: Clinical diagnosis of FECD based on slit-lamp findings, graded accord-ing to Krachmer et al. (1978) as documented in routine care.
  6. Control cohort: No clinical evidence of corneal endothelial disease at baseline (no signs consistent with FECD or other endothelial pathology) as documented in routine care.

Exclusion criteria

Exclusion Criteria:

  1. Corneal scars
  2. Pseudoexfoliation (PEX) syndrome
  3. Glaucoma
  4. Uveitis
  5. Diabetic retinopathy
  6. Other relevant ophthalmic disorders (e.g. retinal degeneration, macular or corneal pa-thologies)
  7. Previous intraocular surgery (including laser procedures)
  8. Ocular trauma (within the past 6 months)
  9. Pregnancy (if applicable, pregnancy must be excluded by a β-hCG test)
  10. CCT > 625μm
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
98 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Fuchs endothelial corneal dystrophy (FECD)

    Patients with Fuchs endothelial corneal dystrophy (FECD). Clinical diagnosis of FECD based on slit-lamp findings, graded according to Krachmer et al. (1978).

  • Non-FECD

    Patients without Fuchs endothelial corneal dystrophy (FECD). Control cohort: No clinical evidence of corneal endothelial disease at baseline (no signs consistent with FECD or other endothelial pathology)

06

What researchers measure

Primary outcomes

  1. Central corneal thickness (CCT, µm) six weeks after routine phacoemulsification cataract surgery, compared between FECD and non-FECD eyes, adjusting for baseline (preoperative) CCT

    The primary endpoint of this study is central corneal thickness (CCT, µm) six weeks after routine phacoemulsification cataract surgery, compared between FECD and non-FECD eyes, adjusting for baseline (preoperative) CCT.

    Time frame: 6 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 28, 2026
StartEst.
Jul 20, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Aug 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07731945
Lead sponsor
Vienna Hospital Association
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Jul 20, 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Aug 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion